Early vericiguat after heart attack for weakened hearts
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether starting the medication vericiguat soon after a heart attack can help people whose hearts are weakened (ejection fraction 45% or lower) and who developed heart failure. Vericiguat is an oral medicine that may reduce strain on the heart and improve outcomes when given early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You had a heart attack and a procedure (like a stent or bypass) to open the blocked artery during this hospital stay.
- You developed heart failure symptoms (like severe breathlessness or swelling) within two weeks after the heart attack, and needed a water pill (diuretic) to manage them.
- Your heart's pumping strength (ejection fraction) is 45% or lower, and a blood test (NT-proBNP) showed high strain on the heart.
- Your kidney function is at least moderately good (eGFR of 15 or higher).
- You do not have severe lung, liver, or heart valve disease, allergies to required medications, or conditions like cardiomyopathy or Takotsubo syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a medication called vericiguat works in people with both chronic kidney disease and heart failure. It aims to see if the drug helps manage these conditions together.
This trial tests whether adding vericiguat to your usual heart failure medicines helps reduce pressure in your lungs and improve symptoms. You will have a CardioMEMS sensor already implanted to monitor your heart, and the study will use its readings to guide your care.
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This study tests whether increasing the doses of standard heart failure medicines shortly after a catheter-based heart valve procedure improves recovery and long-term heart function. It is designed for people with heart failure who had a valve fixed during this hospital stay.
This study tests whether the drug vericiguat helps people with heart failure after a heart attack. The trial looks at people whose heart pumping is weak and who have symptoms despite standard treatment.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.